Plus Therapeutics Reports Q2 2019 Financial and Business Results

    NEXT STORY
    FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
    PREV STORY
    Delcath Systems Announces $9.5 Million Private Placement
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Cellceutix Provides Corporate Update and Reports Q1 Fiscal 2017 Financial Results

    Enrollment Underway in Phase 2b Study of Prurisol for Moderate to Severe Plaque Psoriasis ...

    author_avatar
    NASDAQ Market News

    Calithera Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights

    author_avatar
    NASDAQ Market News

    Nabriva Therapeutics Announces Acceptance of New Drug Applications by the FDA for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults

    author_avatar
    NASDAQ Market News